Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F B Wright

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
European Journal of Clinical Pharmacology|December 10, 2019
The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF)Sine Donnellan, Daniel F B Wright, Jason A Roberts, et al.
Clinical Pharmacokinetics|December 18, 2024
Relative Forgiveness of Different Allopurinol Implementation Patterns in People with Gout and their Impact on Clinical Outcomes: a Simulation StudyMelanie White-Koning, Daniel F B Wright, Dyfrig A Hughes, et al.
Plos One|February 18, 2021
Metformin doses to ensure efficacy and safety in patients with reduced kidney functionIsabelle H S Kuan, Luke C Wilson, Jed C Leishman, et al.
British Journal of Clinical Pharmacology|May 18, 2021
Does the intact nephron hypothesis provide a reasonable model for metformin dosing in chronic kidney disease?Sudeep Pradhan, Stephen B Duffull, Luke C Wilson, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|May 14, 2024
The experiences and perspectives of people with gout on urate self-monitoringToni J F Michael, Jian S Chan, Stephen Hughes, et al.
Drugs in R&D|May 7, 2014
Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin CPaul K L Chin, Daniel F B Wright, Mei Zhang, et al.
British Journal of Clinical Pharmacology|February 15, 2024
The development and evaluation of dose-prediction tools for allopurinol therapy (Easy-Allo tools)Daniel F B Wright, Hailemichael Z Hishe, Sophie L Stocker, et al.
Joint Bone Spine|August 13, 2013
Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromaroneRebecca L Roberts, Mary C Wallace, Daniel F B Wright, et al.
Studies in Health Technology and Informatics|April 22, 2009
Genotypic Approaches to Therapy in Children (GATC): using information technology to improve drug safetyE Wong, B C Carleton, D F B Wright, et al.
British Journal of Clinical Pharmacology|April 19, 2017
Individualising the dose of allopurinol in patients with goutDiluk R W Kannangara, Garry G Graham, Daniel F B Wright, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
European Journal of Clinical Pharmacology|December 10, 2019
The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF)Sine Donnellan, Daniel F B Wright, Jason A Roberts, et al.
Clinical Pharmacokinetics|December 18, 2024
Relative Forgiveness of Different Allopurinol Implementation Patterns in People with Gout and their Impact on Clinical Outcomes: a Simulation StudyMelanie White-Koning, Daniel F B Wright, Dyfrig A Hughes, et al.
Plos One|February 18, 2021
Metformin doses to ensure efficacy and safety in patients with reduced kidney functionIsabelle H S Kuan, Luke C Wilson, Jed C Leishman, et al.
British Journal of Clinical Pharmacology|May 18, 2021
Does the intact nephron hypothesis provide a reasonable model for metformin dosing in chronic kidney disease?Sudeep Pradhan, Stephen B Duffull, Luke C Wilson, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|May 14, 2024
The experiences and perspectives of people with gout on urate self-monitoringToni J F Michael, Jian S Chan, Stephen Hughes, et al.
Drugs in R&D|May 7, 2014
Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin CPaul K L Chin, Daniel F B Wright, Mei Zhang, et al.
British Journal of Clinical Pharmacology|February 15, 2024
The development and evaluation of dose-prediction tools for allopurinol therapy (Easy-Allo tools)Daniel F B Wright, Hailemichael Z Hishe, Sophie L Stocker, et al.
Joint Bone Spine|August 13, 2013
Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromaroneRebecca L Roberts, Mary C Wallace, Daniel F B Wright, et al.
Studies in Health Technology and Informatics|April 22, 2009
Genotypic Approaches to Therapy in Children (GATC): using information technology to improve drug safetyE Wong, B C Carleton, D F B Wright, et al.
British Journal of Clinical Pharmacology|April 19, 2017
Individualising the dose of allopurinol in patients with goutDiluk R W Kannangara, Garry G Graham, Daniel F B Wright, et al.
Pageof 9